Aldeyra Therapeutics (ALDX) Other financing activities (2017 - 2025)
Aldeyra Therapeutics (ALDX) posted Other financing activities of $1.1 million for Q4 2025, up 5427.75% on a QoQ basis from $19616.0 in Q1 2025, and up 209.56% year-over-year from $350279.0 in Q4 2024.
Aldeyra Therapeutics (ALDX) Other financing activities (2017 - 2025) Analysis & Trends
Aldeyra Therapeutics' Other financing activities history runs 9 years deep, the most recent figure standing at $1.1 million for Q4 2025.
- Quarterly Other financing activities rose 209.56% year-over-year to $1.1 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $1.1 million (up 193.14% YoY) and the FY2025 annual result came in at $1.1 million, up 215.16% from the prior year.
- Other financing activities was $1.1 million for Q4 2025 at Aldeyra Therapeutics, up from $19616.0 in the prior quarter.
- Across five years, Other financing activities topped out at $4.0 million in Q1 2021 and bottomed at -$4.6 million in Q4 2021.
- A 5-year average of $129038.7 and a median of $67793.0 in 2023 frame the typical range for Other financing activities.
- Peak annual rise in Other financing activities reached 38890.17% in 2021, while the deepest fall reached 589.69% in 2021.
- Aldeyra Therapeutics' Other financing activities stood at -$4.6 million in 2021, then jumped by 77.49% to -$1.0 million in 2022, then jumped by 108.09% to $83027.0 in 2023, then jumped by 321.89% to $350279.0 in 2024, then jumped by 209.56% to $1.1 million in 2025.
- Business Quant data shows ALDX's Other financing activities at $1.1 million in Q4 2025, $19616.0 in Q1 2025, and $350279.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Aldeyra Therapeutics | 95.00 Mn | 95.00 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.08 Mn |
| Dec 31, 2025 | 1.08 Mn |
| Mar 31, 2025 | 19,616.00 |
| Mar 31, 2025 | 19,616.00 |
| Dec 31, 2024 | 350,279.00 |
| Dec 31, 2024 | 350,279.00 |
| Dec 31, 2023 | 83,027.00 |
| Dec 31, 2023 | 83,027.00 |
| Sep 30, 2023 | 105,810.00 |
| Sep 30, 2023 | 105,810.00 |
| Jun 30, 2023 | -47,267.00 |
| Jun 30, 2023 | -47,267.00 |
| Mar 31, 2023 | 52,559.00 |
| Mar 31, 2023 | 52,559.00 |
| Dec 31, 2022 | -1.03 Mn |
| Dec 31, 2022 | -1.03 Mn |
| Sep 30, 2022 | 1.10 Mn |
| Sep 30, 2022 | 1.10 Mn |
| Mar 31, 2022 | 23,324.00 |
| Mar 31, 2022 | 23,324.00 |